Protocol Summary
Protocol No.LCCC1532-ATLPrincipal InvestigatorBeaven, Anne
PhasePhase I/II
Oncology GroupLymphomaOncology Group
Management GroupCellular Immunotherapy CPO; Clinical Protocol Office; Lymphoma CPO
Age GroupAdultScopeLocal
TitlePhase Ib/II Study of the Administration of T lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma
Applicable Disease SitesHodgkin's Lymphoma
Non-Hodgkins Lymphoma
Drugs InvolvedATLCAR.CD30
StatusOpen
Participating InstitutionsUNC-CH
Eligibility DocumentLCCC 1532-ALT Eligibility Packet Lymphodepletion (Eligibility Criteria + T&E + Prohibited Meds +Admin Ltrs.) Am. 4_ 3-6-17.pdf
ClinicialTrials.gov http://www.clinicaltrials.gov/ct2/show/NCT02690545